Shanghai Pharmaceutical (02607): Amisulpride tablets passed the national health insurance negotiations and were successfully included in the national health insurance catalogue

Zhitong Finance App News, Shanghai Pharmaceutical (02607) issued an announcement. On December 7, 2025, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “National Catalogue of Drugs for Basic Medical Insurance, Maternity Insurance and Work Injury Insurance (2025)”, which will take effect from January 1, 2026. Amisulpride tablets from Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceutical Group Co., Ltd., were successfully included in the “National Health Insurance Catalogue” through national health insurance negotiations.

Amisulpride tablets are an improved dosage form of amisulpride tablets marketed by Sanofi (Sanofi) in France in 1986 to treat schizophrenia in adults. In October 2025, with the approval of the State Drug Administration, Shangyao Zhongxi became the marketing license holder for amisulpride tablets. As of the date of this announcement, no other companies in China have listed amisulpride tablets. According to the IQVIA database, hospital purchases of amisulpride oral preparations in 2024 were RMB 168.41 million.

The Chinese and Western medicines amisulpride tablets were successfully included in the “National Medical Insurance Catalogue”, which is conducive to expanding the market share of this drug, enhancing market competitiveness, and at the same time accumulating valuable experience in carrying out related work for the company's other products.